Tocilizumab-Associated Reversible Cerebral Vasoconstriction: A Case Report.
Alicia Gonzalez-MartinezDaniel Romero-PalaciánJulio Dotor García-SotoPedro SánchezGemma Reig RosellóGustavo Zapata WainbergPublished in: Headache (2019)
Tocilizumab could be a trigger of RCVS. It is important to bear in mind the role of tocilizumab as a possible precipitating factor in order to remove it and reduce complications such as strokes. It is, to our knowledge, the first reversible vasoconstriction syndrome possibly precipitated by tocilizumab published to date.